Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-09-27FDA Approved: METHADONE HYDROCHLORIDE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for methadone hydrochloride from VistaPharm, LLC, indicating approval of a supplemental submission f…
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the ED [Phase 4]
Phase 4 clinical trial investigating low-dose ketamine as an adjunct to morphine for acute pain in the emergency department; the study is te…
-
CLINICAL_TRIALS trial_result · 2023-09-18Clinical Trial Update: Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone [NA]
A completed clinical trial investigating rapid initiation of naltrexone treatment for opioid-use disorder.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders [Phase 3]
A Phase 3 trial evaluated non-invasive vagal nerve stimulation as a treatment for opioid use disorders; the study is completed with results …
-
FDA approval · 2023-09-12FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine) from Indivior Inc., updating the product labeling as part of a sup…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-07Clinical Trial Update: A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. [Phase 2]
Phase 2 study assessing abuse potential of oxymorphone compared with other mu opioid agonists in opioid use disorder; results posted after c…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Suicide Prediction and Prevention for People at Risk for Opioid Use Disorder: Supplement to COMPUTE 2.0 [NA]
A completed clinical trial update focusing on suicide prediction and prevention for individuals at risk for opioid use disorder as a supplem…
-
CLINICAL_TRIALS trial_result · 2023-08-29Clinical Trial Update: Oral Cannabidiol for Opioid Withdrawal [Phase 1, Phase 2]
A Phase 1/2 trial evaluating oral cannabidiol for opioid withdrawal and craving has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Empower Opioid Misuse & Chronic Pain [NA]
A completed clinical trial update related to opioid misuse and chronic pain is posted, but no detailed results are provided here.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Remote Observed Dosing of Suboxone to Improve Clinical Practice [Phase 1, Phase 2]
A phase 1/2 trial evaluating remote observed dosing of Suboxone (buprenorphine/naloxone) to inform clinical practice for opioid-use disorder…
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Minds and Mentors Program (MiMP)- R61 [NA]
Clinical trial update for the Minds and Mentors Program (MiMP) R61 completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder [NA]
A completed clinical trial evaluating a digital therapeutic for opioid use disorder has results posted.
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: Emergency Department Outcomes for Patients With Opioid Use Disorder
Clinical trial update on emergency department outcomes for patients with opioid use disorder completed with results posted in 2023.
-
FDA approval · 2023-07-03FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
The FDA approved a supplemental application for SUBLOCADE (buprenorphine) from Indivior Inc., updating the product labeling to reflect the a…
-
CLINICAL_TRIALS trial_result · 2023-06-28Clinical Trial Update: Assessment of Methadone and Buprenorphine in Interstitial Fluid
Completed clinical trial assessing methadone and buprenorphine levels in interstitial fluid for opioid use disorder; results posted in 2023.
-
FDA approval · 2023-06-26FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
The FDA approved a supplemental application for buprenorphine hydrochloride (generic buprenorphine HCl) submitted by PAI Holdings/PAI Pharma…
-
FDA approval · 2023-06-26FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for buprenorphine and naloxone by Rhodes Pharmaceuticals L.P., supporting the continued use of this …
-
FDA approval · 2023-06-26FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine and naloxone submitted by PAI Holdings (PAI Pharma).
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Emergency Department Longitudinal Integrated Care [NA]
Completed clinical trial evaluating longitudinal integrated care for opioid-use disorder in the emergency department; results posted in 2023…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: PROUD Study - Preventing Opioid Use Disorders [Phase 4]
Phase 4 clinical trial update for the PROUD study on preventing opioid use disorders; the study has been terminated with results posted in 2…
-
FDA approval · 2023-06-14FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine from Actavis Pharma, Inc., indicating regulatory approval related to this generic …
-
FDA approval · 2023-06-14FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)
The FDA approved a supplemental application for a generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate product from Spec…
-
FDA approval · 2023-06-13FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Accord Healthcare, Inc)
FDA approved a supplemental application for Accord Healthcare's generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate pro…
-
FDA approval · 2023-06-09FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for a generic buprenorphine and naloxone product from Lannett Company, Inc.
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: Pharmacokinetic Study of Vivitrol in Healthy Participants [Phase 1]
A Phase 1 pharmacokinetic study of Vivitrol in healthy participants has completed, with results posted.